Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals
NCT06973174 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2026-01-28
Summary
Background. Bacillus cereus group (Bc) comprises twenty-six closely related species of spore-forming environmental bacteria. Recently, increased sepsis and septic shock caused by Bc were reported in preterm neonates (PN), and the mortality rate can reach up to 30%. Using Whole Genome Sequencing (WGS) increasingly used to characterize Bc strains, The team aimed to determine an accurate identification to the species level of the strains involved in Bc invasive infections in preterm neonates in France and study their virulome profile.Methods. The team performed WGS for 40 neonate clinical strains responsible for invasive infections in PN. A screening of virulence genes was performed to characterize strains associated with poor prognosis. Clinical data were collected and all clinical and genomic findings were analyzed for risk factors for death.
"
Conditions
Interventions
- BIOLOGICAL
-
Premature neonates with invasive infection caused by Bacillus cereus
The whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nice
lead OTHER
Eligibility
- Max Age
- 143 Days
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-01-01
- Primary Completion
- 2026-07-30
- Completion
- 2026-12-30
Countries
- France
Study Locations
More Related Trials
-
Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology
NCT06267352 ·Status: NOT_YET_RECRUITING
-
Antibiotic Therapy for Early Onset Neonatal Sepsis
NCT03932123 ·Status: RECRUITING
-
Neonatal Bacterial Colonization Study
NCT03896893 ·Status: UNKNOWN ·Phase: NA
-
Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis
NCT02143154 ·Status: COMPLETED
-
Validation of Biomarkers Performance to Reduce Antibiotics overUse in newBorns With Suspected Clinical Signs of InfectionS
NCT06058819 ·Status: RECRUITING
-
SEPSIS: L. Plantarum Trial
NCT05180201 ·Status: COMPLETED ·Phase: PHASE2
-
Resistant Bacteria in Children in France
NCT06036628 ·Status: COMPLETED
-
Treatment of Enterococcus Faecalis Bacterem
NCT07299539 ·Status: RECRUITING
-
Promoting Optimal Treatment Choices in Neonates With Suspected Early-Onset Sepsis
NCT06845332 ·Status: RECRUITING
-
Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants
NCT00189384 ·Status: UNKNOWN ·Phase: PHASE3
-
Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
NCT04535661 ·Status: RECRUITING
-
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
NCT00850122 ·Status: COMPLETED ·Phase: PHASE1
-
Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China
NCT05089760 ·Status: UNKNOWN
-
Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics
NCT07111793 ·Status: RECRUITING ·Phase: NA
-
Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates
NCT00873327 ·Status: COMPLETED ·Phase: PHASE1
-
Catheter Biofilm Microbiome in Infected Neonatal Catheters.
NCT01985737 ·Status: COMPLETED
-
A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome
NCT02477423 ·Status: COMPLETED ·Phase: NA
-
Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
NCT05352997 ·Status: COMPLETED
-
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
NCT07202377 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy And Safety Of Short Course Antibiotic Therapy In Preterm Neonates With Early Onset Sepsis
NCT06197269 ·Status: COMPLETED ·Phase: NA
-
Neonatal Vancomycin Trial
NCT02790996 ·Status: TERMINATED ·Phase: PHASE2
-
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
NCT02967432 ·Status: COMPLETED ·Phase: PHASE2
-
Population Pharmacokinetics of Amikacin in Neonates
NCT04867135 ·Status: COMPLETED
-
Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis
NCT03453177 ·Status: COMPLETED ·Phase: PHASE2
-
Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation
NCT06974994 ·Status: RECRUITING ·Phase: NA